BLTE Belite Bio Inc ADR

$120.56

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Belite Bio Inc ADR

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.

Website: https://www.belitebio.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1889109
Address
12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, CA
Valuation
Market Cap
$1.82B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
12.49
Performance
EPS
$-1.18
Dividend Yield
—
Profit Margin
0.00%
ROE
-30.60%
Technicals
50D MA
$60.94
200D MA
$58.26
52W High
$86.53
52W Low
$32.50
Fundamentals
Shares Outstanding
32M
Target Price
$85.00
Beta
-1.52

BLTE EPS Estimates vs Actual

● Estimated
● Actual

BLTE News & Sentiment

Nov 02, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
SAN DIEGO, Nov. 02, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc. ( NASDAQ: BLTE ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United Kingdom's Medicines ...
Nov 02, 2025 • Benzinga SOMEWHAT-BULLISH
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant - Belite Bio ( NASDAQ:BLTE )
MHRA response is based on the Phase 3 DRAGON interim analysis results
Oct 31, 2025 • Benzinga NEUTRAL
CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 - Belite Bio ( NASDAQ:BLTE ) , 51 Talk Online Education ( AMEX:COE )
NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows:
Oct 29, 2025 • Benzinga SOMEWHAT-BULLISH
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th - Belite Bio ( NASDAQ:BLTE )
SAN DIEGO, Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio Inc ( NASDAQ:BLTE ) ( "Belite" or the "Company" ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that ...
Oct 29, 2025 • Benzinga SOMEWHAT-BULLISH
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference - Belite Bio ( NASDAQ:BLTE )
SAN DIEGO, Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio Inc ( NASDAQ:BLTE ) ( "Belite" or the "Company" ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that ...
Oct 15, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
SAN DIEGO, Oct. 15, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc. ( NASDAQ: BLTE ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Center for Drug ...
Sentiment Snapshot

Average Sentiment Score:

0.185
50 articles with scored sentiment

Overall Sentiment:

Bullish

BLTE Reported Earnings

Aug 11, 2025
Jun 30, 2025 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: 20.5%
May 13, 2025
Mar 31, 2025 (Pre market)
0.1 Surprise
  • Reported EPS: $-0.27
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: 27.0%
Mar 17, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: 0.0%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: 3.5%
Aug 09, 2024
Jun 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: -19.2%
May 13, 2024
Mar 31, 2024 (Post market)
0.01 Surprise
  • Reported EPS: $-0.27
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 3.6%
Mar 11, 2024
Dec 31, 2023 (Post market)
0.05 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 16.7%
Nov 13, 2023
Sep 30, 2023 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: -25.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 13.3%

Financials